< Zurück zu den aktuellen Neuigkeiten & Events

UPC

UK – ratifying the UPC – could we, should we?

September 2016

Two interesting documents on Brexit and the UPC have been published; the UK Chartered Institute of Patent Attorneys (CIPA) view on the UPC in light of Brexit, which is supported by the second document, an Opinion from Legal Counsel.

On the face of it, these documents paint a positive picture – the UK “could” continue to participate in the Unitary Patent by entering into a new international agreement with the participating EU Member States. The UK could even host the Life Sciences/Chemistry section of the UPC, but changes would have to be made to the UPC Agreement. However, the complexity of the additional agreements and amendments that would need to put in place should not be underestimated.

Whilst the view that the UK “could” join the Unified Patent Court and can remain part of the UP system after the UK leaves the European Union may be legally correct in the opinion of Counsel, the changes required to make that happen, may concern the other EU Member State participants to the UP & UPC agreements.

However, ratifying now, and exiting later, is likely to add even further to the complexity of these issues, but hasn’t been ruled out.  As reported by WIPR, Margot Fröhlinger, principal director of patent law and multilateral affairs at the EPO, the EPO “wants the UK’s involvement” but … “if the UK does not ratify or waits to see how Brexit plays out, the UPC members will have to “find a way to go ahead without the UK””.

HGF continues to monitor the situation regarding BREXIT and the UPC closely; we believe the UP and UPC systems would be stronger and more beneficial for businesses with UK involvement, but suspect the political obstacles and issues of sovereignty that need to be tackled, as well as agreements that may need to be put in place, could take as many years to agree as the UP & UPC agreements themselves have taken.

This update was prepared by Martyn Fish, Partner. If you would like further advice on this or any other matter please contact Martyn or your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Aktuelle Neuigkeiten

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Weiterlesen
Event - 5. November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Veranstaltungsdetails

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Weiterlesen

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Weiterlesen
Event - 14. Oktober 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Veranstaltungsdetails

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Weiterlesen

T 0792/24: Novelty and Inventiveness of Second Medical Use Claims

The EPO Board of Appeal’s decision in T 0792/24 provides helpful guidance on the assessment of novelty and inventive step for European second medical use claims. In light of a …

Weiterlesen

HGF hoch platziert im Legal 500 2026

Die Rangliste des Legal 500 UK 2026 wurde veröffentlicht und HGF wurde erneut in mehreren Regionen und Praxisbereichen platziert. HGF ist weiterhin in der Spitzenklasse des britischen PATMA – Markenzeichen …

Weiterlesen